| Vol. 4.27 – 11 December, 2020 |
| |
|
|
| Scientists demonstrated that Aldob suppressed Akt activity and tumor growth through a protein complex containing Aldob, Akt, and protein phosphatase 2A (PP2A), leading to inhibition of cell viability, cell cycle progression, glucose uptake, and metabolism. [PLoS Biology] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors demonstrated that integrated analysis and engineering of gene regulatory networks in PSC-derived multilineage human liver organoids directed maturation and vascular morphogenesis in vitro. [Cell Systems] |
|
|
|
| Researchers report that myeloid-specific Foxo1 knockout (Foxo1M-KO) mice were resistant to oxidative stress-induced hepatocellular damage with reduced macrophage/neutrophil infiltration, and pro-inflammatory mediators in liver ischemia/reperfusion injury. [Cell Death & Differentiation] |
|
|
|
| Investigators found that K62 residues were deacetylated, which was related to the prognosis of hepatocellular carcinoma. Further studies indicated that HDAC8 bound and deacetylated the K62 residue of PKM2. [Cell Death & Disease] |
|
|
|
| βMCA suppressed lipid accumulation in mouse primary hepatocytes exposed to palmitic acid/oleic acid, but cholic acid did not. In addition, Cyp7a1 expression seemed to be related to lipid accumulation in hepatocytes. [Laboratory Investigation] |
|
|
|
| Overexpression of stemness factors NANOG, OCT4 and SOX2 by introduction of gene constructs in Hep3B cells suppressed two miRNA expression levels. Treatment of chromeceptin, an IGF signaling pathway inhibitor, decreased numbers of tumorsphere and inhibited the AKT/mTOR pathway. [Scientific Reports] |
|
|
|
| Researchers employed next generation sequencing to map alterations in the expression of microRNAs occurring across a detailed time course of culture-induced transdifferentiation of primary human hepatic stellate cells, a key event in fibrogenesis. [Scientific Reports] |
|
|
|
| Fibronectin containing extra domain A (FN-EDA) was positively correlated with pathological angiogenesis in hepatic fibrosis, and a reduction in FN-EDA expression was associated with diminished intrahepatic angiogenesis and fibrosis. [Cell Death Discovery] |
| |
|
|
|
| The authors discuss the suite of hepatcellular carcinoma (HCC)-associated genetic changes and describe recent studies that provide evidence for an evolving functional model and its implications for understanding and targeting HCC progression. [Experimental and Molecular Medicine] |
|
|
|
|
| Arbutus Biopharma Corporation announced additional clinical data from an ongoing Phase Ia/Ib clinical trial with AB-729, its proprietary GalNAc delivered RNAi compound. [Arbutus Biopharma Corporation] |
|
|
|
| Altimmune, Inc. announced that it has commenced dosing in a Phase I single ascending dose and multiple ascending dose clinical study of ALT-801. ALT-801 is a long-acting GLP-1/glucagon receptor dual agonist being developed for the treatment of non-alcoholic steatohepatitis (NASH), which is expected to affect more than 13 million adults in the United States. [Altimmune, Inc.] |
|
|
|
|
| January 15 – 16, 2021 Virtual |
|
|
|
|
|
| University of Oslo – Oslo, Norway |
|
|
|
| University of Cincinnati – Cincinnati, Ohio, United States |
|
|
|
| NIH National Cancer Institute – Bethesda, Maryland, United States |
|
|
|
| Karolinska Institutet – Stockholm, Sweden |
|
|
|
| Stanford University – Stanford, California, United States |
|
|
|
|